Authors: BOHN RL AVORN J GLYNN RJ CHOODNOVSKIY I HASCHEMEYER R ALEDORT LM

Citation: Rl. Bohn et al., PROPHYLACTIC USE OF FACTOR-VIII - AN ECONOMIC-EVALUATION, Thrombosis and haemostasis, 79(5), 1998, pp. 932-937

Authors: BOHN RL AVORN J GLYNN RJ CHOODNOVSKIY I HASCHEMEYER R ALEDORT LM

Citation: Rl. Bohn et al., PROPHYLACTIC USE OF FACTOR-VIII - ARE THE CLINICAL BENEFITS WORTH THEADDITIONAL COST, Blood, 86(10), 1995, pp. 2431-2431

Authors: SERUR D RIGGIO RR HASCHEMEYER R FOTINO M WANG JC CHEIGH JS SAAL SD STUBENBORD WR RUBIN AL STENZEL KH SUTHANTHIRAN M

Citation: D. Serur et al., EFFICACY OF A CALCIUM-ANTAGONIST SUPPLEMENTED IMMUNOSUPPRESSIVE REGIME IN RENAL-ALLOGRAFT RECIPIENTS, Journal of the American Society of Nephrology, 5(3), 1994, pp. 1036-1036

Authors: NAKAJIMA F KHANNA A XU GP LAGMAN M HASCHEMEYER R MOURADIAN J WANG JC STENZEL KH RUBIN AL SUTHANTHIRAN M

Citation: F. Nakajima et al., IMMUNOTHERAPY WITH ANTI-CDS MONOCLONAL-ANTIBODIES AND RECOMBINANT INTERLEUKIN-2 - STIMULATION OF MOLECULAR PROGRAMS OF CYTOTOXIC KILLER-CELLS AND INDUCTION OF TUMOR-REGRESSION, Proceedings of the National Academy of Sciences of the United Statesof America, 91(17), 1994, pp. 7889-7893